Mass Spectrometry Adopted by Clinical Laboratories Around the World

News provided by

Dec 02, 2016, 08:45 ET

NEW YORK, December 2, 2016 /PRNewswire/ --

Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories. MS ionizes chemical species and sorts the ions based on mass to charge ratio. It can be used in various fields, applied to pure samples and complex mixtures. According to a recent research published by P&S Market Research, the global MS market accounted for $4.9 billion revenue in 2015, and it is expected to grow at a CAGR of 8.1% during 2016-2022, crossing the $7.3 billion mark by 2022. Pressure Biosciences Inc. (OTC: PBIO), Danaher Corporation (NYSE: DHR), Qiagen NV (NASDAQ: QGEN), Thermo Fisher Scientific Inc. (NYSE: TMO), Illumina Inc. (NASDAQ: ILMN)

The global MS market is witnessing high growth rate thanks to technological advancements in mass spectrometers and continuously increasing expenditure on healthcare around the world. Besides clinical testing, the MS analytic technique can be used for drug discovery and development, proteomics (the study of proteins), and also detecting of microorganisms in food helping to quality control and food safety. The market potential behind the technique is reflected in its contribution to the quality of patient care. Along with that, improvements in analytical performance in areas such as toxicology, endocrinology, and biochemical genetics

Pressure BioSciences, Inc. (OTCQB: PBIO) is a life sciences company focused on the development and commercialization of a novel platform technology called Pressure Cycling Technology (PCT), designed to control bio-molecular interactions. The company's instrument, the Barocycler, and the ProteoSolveLRS kit for the detergent-free extraction of proteins from lipid-rich samples, together make up the PCT Sample Preparation System. This system can be used for a wide range of applications including, sample preparation for genomic, proteomic, and small molecule studies, protein purification and much more.

Pressure BioSciences, Inc. recently announced an exclusive co-marketing agreement with SCIEX, a company focuses on science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR). Under the agreement, the companies will jointly promote Pressure BioSciences' PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation. SCIEX has a particular interest proteomics, which is why a partnership with Pressure BioSciences might be productive.

SCIEX's expertise in mass spectrometry provides marketing personnel and a worldwide distribution network that Pressure BioSciences, Inc. needs and will utilize. The co-marketing agreement will act to introduce Pressure BioSciences and its technology platform.

In the latest quarterly financial report, the company reported a 55.8% increase in revenue and a 13.4% decrease in operating costs, despite an increase in its marketing and sales efforts. Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We believe these and other recent successes have positioned us well for continued growth and future profitability. However, much remains to be done. It is important that we continue to build upon these recent successes. In that vein, it is imperative that we expand and enhance our current financial, operational, and technical capabilities, and that we find additional ways to help ensure that our progress is seen and understood by the worldwide financial and investor communities. To that end, we are committed to using funds from the PIPE Financing, Line-of-Credit, and Product Sales to help achieve these very important and timely goals. This may include, among other things, additions to staff, independent agents, distributors, and consultants focused primarily in sales and marketing,

Qiagen NV (NASDAQ: QGEN) and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. The company has a wide variety of products under its portfolio, among them is the Qproteome FFPE Tissue Kit, which enables efficient extraction of full-length proteins from FFPE tissues. Qiagen put an emphasis on investigating the suitability of proteins isolated using the Qproteome FFPE Tissue Kit for mass spectrometric (MS) analysis. The company revealed that a total of 635 unique peptides (frozen sample) and 567 unique peptides (FFPE sample) were isolated and identified by the MS technique.

Thermo Fisher Scientific Inc. (NYSE: TMO) is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company owns an exclusive Thermo Fisher Scientific workflow solution for proteins and peptides, which is enabled through proprietary MSIA D.A.R.T.'S™ technologies and designed to improve hybrid mass spectrometry bio-analysis, specifically biologic and biomarker bio-analysis.

Illumina Inc. (NASDAQ: ILMN) offers sequencing and array-based solutions for genetic analysis. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals. The company has a long history of researching and applying mass spectrometry in its business operations, and has participated in or published extensive research papers as well as articles on the potential benefits of the MS analysis technique. One such article was called, "Predicting immunogenic tumor mutations by combining mass spectrometry and exome sequencing."

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated six thousand dollars for financial news dissemination and pr services by pressure biosciences inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: [email protected], +1-877-601-1879

Url: FinancialBuzz.com

SOURCE FinancialBuzz.com